share_log

Wedbush Reiterates Outperform on TScan Therapeutics, Maintains $10 Price Target

Moomoo 24/7 ·  Apr 23 13:17

Wedbush analyst David Nierengarten reiterates TScan Therapeutics (NASDAQ:TCRX) with a Outperform and maintains $10 price target.

Disclaimer: This content is for informational and educational purposes only and does not constitute a recommendation or endorsement of any specific investment or investment strategy. Read more
    Write a comment